PEDs, Financial Incentives, and the Problems They Create
Yesterday, MLB announced that Marlon Byrd has been suspended 162 games for failing a second PED test, which will effectively end his big league career. As a guy who turns 39 in a few months, he was already nearing the end of his days as a productive player anyway, and with a chunk of the suspension carrying over to next season, it’s unlikely any team will offer him a contract this winter. So this is probably it for Marlon Byrd.
But having his career end like this isn’t much solace for the pitchers that Byrd faced, or the teams that lost games in which the Indians gained an advantage from having him on the field. For instance, here’s Dan Haren’s comments in the wake of the news coming out yesterday.
@Ken_Rosenthal can I get back all the home runs he hit off me please? Thanks
— dan haren (@ithrow88) June 1, 2016
Also last year magically returned from a broken wrist in 16 days, at age 38. Proceeded to homer off me that day. https://t.co/7ubQOpskCk
— dan haren (@ithrow88) June 1, 2016
This is one of the issues the current system can’t really address. Sure, Byrd’s career is likely over, but maybe it would have been over four years ago had he not started looking for chemical assistance, and so what did he really lose by taking the banned substances? For players in his position, on the bubble of the major leagues, the incentive to use will always be larger than the costs of getting caught as long as one doesn’t care too terribly much about their reputation.
So every time a player fails a test and gets suspended, there’s a push for a different set of punishments, ones that would try to reduce the financial incentive to take PEDs, or at least increase the cost of getting caught. The most common suggestion is to allow teams to void the contracts of players who fail drug tests, so that players can’t use the money to secure a large financial commitment, then benefit from that commitment even after the suspension ends. Unfortunately, this suggestion is highly problematic.